UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Journal of medicinal chemistry, 2018-08, Vol.61 (16), p.6964-6982

2018

Volltextzugriff (PDF)

Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress

Drug development research, 2021-09, Vol.82 (6), p.852-860

2021

Volltextzugriff (PDF)

Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice

International immunopharmacology, 2024-12, Vol.142 (Pt A), p.113029, Article 113029

2024

Volltextzugriff (PDF)

Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

Diabetes, metabolic syndrome and obesity, 2014-01, Vol.7 (default), p.73-84

2014

Volltextzugriff (PDF)

Effect of GLP-1 based therapies on diabetic dyslipidemia

Current diabetes reviews, 2014-01, Vol.10 (4), p.238-250

2014

Volltextzugriff (PDF)

HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases

Drug research (Stuttgart), 2024-09, Vol.74 (7), p.325-334

2024

Volltextzugriff (PDF)

Therapeutic Potential of Diacerein in Management of Pain

Current Drug Research Reviews, 2022-01, Vol.14 (3), p.215-224

2022

Volltextzugriff (PDF)

Selective Thyromimetics Using Receptor and Tissue Selectivity Approaches: Prospects for Dyslipidemia

Journal of medicinal chemistry, 2012-06, Vol.55 (12), p.5649-5675

2012

Volltextzugriff (PDF)

Age-related changes in hematological and biochemical profiles of Wistar rats

Laboratory Animal Research, 2024, 40(1), , pp.84-95

2024

Volltextzugriff (PDF)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Current research in pharmacology and drug discovery, 2022, Vol.3, p.100102-100102, Article 100102

2022

Volltextzugriff (PDF)

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase‐4, for the treatment of Type 2 diabetes mellitus

British journal of pharmacology, 2017-07, Vol.174 (14), p.2346-2357

2017

Volltextzugriff (PDF)

Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: Evidence of local efficacy without systemic side effect

Medicine in drug discovery, 2022-12, Vol.16, p.100142, Article 100142

2022

Volltextzugriff (PDF)

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice

Canadian journal of physiology and pharmacology, 2013-12, Vol.91 (12), p.1009-1015

2013

Volltextzugriff (PDF)

Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone

Current molecular pharmacology, 2019-01, Vol.12 (2), p.139-146

2019

Volltextzugriff (PDF)

Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease

Cardiovascular & hematological agents in medicinal chemistry, 2018, Vol.16 (1), p.35-43

2018

Volltextzugriff (PDF)

Role of mineralocorticoid receptor antagonists in kidney diseases

Drug development research, 2021-05, Vol.82 (3), p.341-363

2021

Volltextzugriff (PDF)

Optimization of 1,2,5-Thiadiazole Carbamates as Potent and Selective ABHD6 Inhibitors

ChemMedChem, 2015-02, Vol.10 (2), p.253-265

2015

Volltextzugriff (PDF)

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect

Pharmacological reports, 2012-01, Vol.64 (1), p.140-149

2012

Volltextzugriff (PDF)

Antinociceptive activity of alcoholic extract of Hemidesmus indicus R.Br. in mice

Journal of ethnopharmacology, 2005-11, Vol.102 (2), p.298-301

2005

Volltextzugriff (PDF)

Therapeutic potential of coagonists of glucagon and GLP-1

Cardiovascular & hematological agents in medicinal chemistry, 2014-01, Vol.12 (2), p.126-133

2014

Volltextzugriff (PDF)

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model

Drug research, 2017-04, Vol.67 (4), p.223-227

2017

Volltextzugriff (PDF)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

World journal of diabetes, 2018-06, Vol.9 (6), p.80-91

2018

Volltextzugriff (PDF)

Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (奥美拉唑改善唾液素-4 对db/db小鼠的减肥与降糖作用)

Journal of diabetes, 2013-06, Vol.5 (2), p.163-171

2013

Volltextzugriff (PDF)

Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor

Journal of diabetes, 2015-09, Vol.7 (5), p.708-717

2015

Volltextzugriff (PDF)

Discovery of Orally Active, Potent, and Selective Benzotriazole-Based PTP1B Inhibitors

ChemMedChem, 2011-06, Vol.6 (6), p.1011-1016

2011

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(95)
Berichte
(2)

Sprache

Englisch
(97)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress

Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice

Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

Effect of GLP-1 based therapies on diabetic dyslipidemia

HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases

Therapeutic Potential of Diacerein in Management of Pain

Selective Thyromimetics Using Receptor and Tissue Selectivity Approaches: Prospects for Dyslipidemia

Age-related changes in hematological and biochemical profiles of Wistar rats

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase‐4, for the treatment of Type 2 diabetes mellitus

Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: Evidence of local efficacy without systemic side effect

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice

Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone

Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease

Role of mineralocorticoid receptor antagonists in kidney diseases

Optimization of 1,2,5-Thiadiazole Carbamates as Potent and Selective ABHD6 Inhibitors

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect

Antinociceptive activity of alcoholic extract of Hemidesmus indicus R.Br. in mice

Therapeutic potential of coagonists of glucagon and GLP-1

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (奥美拉唑改善唾液素-4 对db/db小鼠的减肥与降糖作用)

Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor

Discovery of Orally Active, Potent, and Selective Benzotriazole-Based PTP1B Inhibitors

Suchergebnisse filtern